Structure of the recombinant RNA polymerase from African Swine Fever Virus

Simona Pilotto,Michal Sýkora,Gwenny Cackett,Christopher Dulson,Finn Werner
DOI: https://doi.org/10.1038/s41467-024-45842-7
IF: 16.6
2024-02-21
Nature Communications
Abstract:Abstract African Swine Fever Virus is a Nucleo-Cytoplasmic Large DNA Virus that causes an incurable haemorrhagic fever in pigs with a high impact on global food security. ASFV replicates in the cytoplasm of the infected cell and encodes its own transcription machinery that is independent of cellular factors, however, not much is known about how this system works at a molecular level. Here, we present methods to produce recombinant ASFV RNA polymerase, functional assays to screen for inhibitors, and high-resolution cryo-electron microscopy structures of the ASFV RNAP in different conformational states. The ASFV RNAP bears a striking resemblance to RNAPII with bona fide homologues of nine of its twelve subunits. Key differences include the fusion of the ASFV assembly platform subunits RPB3 and RPB11, and an unusual C-terminal domain of the stalk subunit vRPB7 that is related to the eukaryotic mRNA cap 2 ́-O-methyltransferase 1. Despite the high degree of structural conservation with cellular RNA polymerases, the ASFV RNAP is resistant to the inhibitors rifampicin and alpha-amanitin. The cryo-EM structures and fully recombinant RNAP system together provide an important tool for the design, development, and screening of antiviral drugs in a low biosafety containment environment.
multidisciplinary sciences
What problem does this paper attempt to address?
The paper mainly addresses the following key issues: 1. **Production of Recombinant African Swine Fever Virus (ASFV) RNA Polymerase**: Researchers successfully produced catalytically active recombinant ASFV RNA polymerase in insect cells, with yields sufficient for functional characterization and inhibitor screening, without the need to operate in high biosafety facilities. 2. **Functional Assays and Inhibitor Screening Methods**: A non-specific in vitro transcription assay was developed to detect the catalytic activity of recombinant ASFV RNA polymerase. Using this method, potential inhibitors were screened, and it was found that ASFV RNA polymerase is resistant to two common RNA polymerase inhibitors, α-amanitin and rifampicin. 3. **High-Resolution Cryo-EM Structural Analysis**: High-resolution cryo-EM structures of ASFV RNA polymerase in different conformational states were resolved, revealing its high structural conservation with eukaryotic RNA polymerase II. Additionally, ASFV-specific structural features were discovered, such as the fusion of the vRPB7 subunit with the eukaryotic mRNA capping enzyme 2'-O-methyltransferase 1. 4. **New Tools for Antiviral Drug Design and Development**: These structures, along with the fully recombinant RNA polymerase system, provide important tools for designing, developing, and screening antiviral drugs in low biosafety environments. In summary, this paper lays the foundation for understanding the working mechanism of ASFV RNA polymerase and developing antiviral drugs against the virus by addressing issues related to the preparation, functional detection, and structural analysis of recombinant ASFV RNA polymerase.